From the Wires
Elsevier Selected to Publish Cytotherapy: The Journal of Cell Therapy
By: PR Newswire
Jan. 7, 2013 04:48 AM
AMSTERDAM, January 7, 2013 /PRNewswire/ --
Official journal of the International Society for Cellular Therapy (ISCT) to be published by Elsevier beginning January 2013
Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to announce that the International Society for Cellular Therapy (ISCT) has selected Elsevier to publish Cytotherapy: The Journal of Cell Therapy effective January 2013.
"Elsevier presented ISCT with unsurpassed reach into the global medical community, top class publishing services, and significant experience in this field. We are extremely confident that our collaboration with Elsevier will not only help Cytotherapy grow for the benefit of our members and readers, but also for the benefit of all scientists, technologists, regulators, manufacturing experts and others dedicated to translational development of safe and effective cell therapies," said ISCT President, Kurt Gunter, MD, FASCP.
Cytotherapy is a highly influential publication in the mainstream of the rapidly expanding field of cell-based treatments for cancer, degenerative disorders, immunotherapy and stem cell transplantation. Cytotherapy publishes cutting edge findings, clinical trials of cell-based therapies, and news and opinion on all aspects of these disciplines. The journal focuses especially on the practical translation of scientific developments in the laboratory into clinical practice. Cytotherapy is an essential global resource for clinical researchers, oncologists, hematologists, doctors, and regulatory experts involved in cell processing and therapy.
Senior Editor of Cytotherapy, John Barrett, MD, commented, "What matters is ensuring that new peer-reviewed treatments, developments, and studies reach as many specialists working with cell therapies as possible. In this, I believe Elsevier offers an unrivaled opportunity to help the journal achieve this goal."
Glen Campbell, Executive Vice President at Elsevier added, "Cytotherapy is an established and reputable journal and we are honored that the International Society for Cellular Therapy selected Elsevier as their publishing partner. Together, we will ensure that this prestigious title develops further as the leading global forum and resource for developing and supporting innovative cellular therapies."
For more information go to: http://www.journals.elsevier.com/cytotherapy
ISCT is a global association driving the translation of scientific research to deliver innovative cellular therapies to patients. Since 1992, ISCT has been the leading global forum for developing and supporting innovative cellular therapies through communication, education and training. ISCT fosters international translational research, informs national and global regulatory framework development and harmonization, drives commercialization strategies, and educates principal investigators, lab directors, technologists, regulators and commercial stakeholders. http://www.celltherapysociety.org
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Latest AJAXWorld RIA Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week